

1. Record Nr.	UNINA9911049063503321
Autore	Gukasyan Hovhannes J
Titolo	Antibody Drug Conjugates : Design, Discovery, and Development / / edited by Hovhannes J. Gukasyan, Ashutosh Kulkarni
Pubbl/distr/stampa	Cham : , : Springer Nature Switzerland : , : Imprint : Springer, , 2026
ISBN	3-031-89319-0
Edizione	[1st ed. 2026.]
Descrizione fisica	1 online resource (306 pages)
Collana	AAPS Advances in the Pharmaceutical Sciences Series, , 2210-738X ; ; 52
Altri autori (Persone)	Gukasyan
Disciplina	615.36
Soggetti	Pharmacology Pharmacy Pharmaceutical chemistry Pharmaceutics
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Nota di contenuto	Commercialized ADCs: A Market Snapshot for Exemplification -- Application of ADCs to Therapeutic Areas Outside of Oncology -- Regulatory framework for the manufacturing and marketing of ADCs -- Conjugation Chemistry and Chemical Design for the Discovery and Development of Antibody Drug Conjugates -- Clinical Pharmacology Considerations in Antibody-Drug Conjugates Development -- Bioanalytical Methodologies for Pharmacokinetic Characterization of Antibody Drug Conjugates -- Toxicology Considerations on Antibody- Drug Conjugate Discovery and Development -- Considerations for Antibody Drug Conjugate Design Stability and Formulation.
Sommario/riassunto	This volume provides a comprehensive recapitulation of structure- activity relationship (SAR) from a mechanism of action point of view for this unique therapeutic modality, in a largely disease agnostic manner. From a disease biology and pharmacology perspective, the cellular target and drug-conjugate selection, considerations on liker -chemistry and -antibody ratio, and formulation science and technology, to get from bench to bedside (i.e. from a laboratory to the systemic circulation in a patient). The book also provides an understanding around target binding and drug/"payload" release mechanisms. Furthermore, pharmacokinetic and safety pharmacological aspects from

a regulatory and clinical perspective are discussed, along with current chemistry, manufacturing, controls guidance and emerging novel delivery devices or technologies. The key differentiation in Antibody Drug Conjugates is the clinical and development discussion, that offers pragmatic considerations in medical product development, IP, regulatory considerations, among others. Furthermore, we discuss the topic as a platform, in a disease agnostic manner.

---